Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)

類似資料

• Interleukin-6 and other cytokine blockade in COVID-19 hyperinflammation
  著者:: Latika Gupta, 等
  出版事項: (2020-01-01)
• Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
  著者:: Liu, Bingwen, 等
  出版事項: (2020)
• Interleukin‐6 blockade treatment for COVID‐19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia
  著者:: Ranger, Amita, 等
  出版事項: (2020)
• Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
  著者:: Zhang, Chi, 等
  出版事項: (2020)
• The conundrum of interleukin-6 blockade in COVID-19
  著者:: Campochiaro, Corrado, 等
  出版事項: (2020)